Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Colin J, Anderson"'
Autor:
Megan H. Jagosky, Colin J. Anderson, James T. Symanowski, Nury M. Steuerwald, Carol J. Farhangfar, Emily A. Baldrige, Jennifer H. Benbow, Michael B. Livingston, Joshua C. Patt, Will A. Ahrens, Jeffrey S. Kneisl, Edward S. Kim
Publikováno v:
Cancer Medicine, Vol 12, Iss 6, Pp 7029-7038 (2023)
Abstract Purpose Patients with unresectable dedifferentiated liposarcoma (DDLPS) have poor overall outcomes. Few genomic alterations have been identified with limited therapeutic options. Experimental Design Patients treated at Levine Cancer Institut
Externí odkaz:
https://doaj.org/article/7e061913e58d4d3093d3ab4b289a48b5
Autor:
Daniel K. Knewitz, Colin J. Anderson, William T. Presley, MaryBeth Horodyski, Mark T. Scarborough, Margaret R. Wallace
Publikováno v:
Sarcoma, Vol 2021 (2021)
Neurofibromatosis type 1 (NF1) is an autosomal dominant tumor syndrome in which benign plexiform neurofibromas are at risk of transforming into malignant peripheral nerve sheath tumors (MPNSTs), a very rare soft-tissue sarcoma. The prognosis of patie
Externí odkaz:
https://doaj.org/article/ec11fc9e59ae4c25a66042d1d27b9802
Autor:
Megan H, Jagosky, Colin J, Anderson, James T, Symanowski, Nury M, Steuerwald, Carol J, Farhangfar, Emily A, Baldrige, Jennifer H, Benbow, Michael B, Livingston, Joshua C, Patt, Will A, Ahrens, Jeffrey S, Kneisl, Edward S, Kim
Publikováno v:
Cancer Medicine. 12:7029-7038
Patients with unresectable dedifferentiated liposarcoma (DDLPS) have poor overall outcomes. Few genomic alterations have been identified with limited therapeutic options.Patients treated at Levine Cancer Institute with DDLPS were identified. Next gen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::987f34a322de0cc7dffc986d5ebe7bf4
https://doi.org/10.1002/cam4.5502
https://doi.org/10.1002/cam4.5502
Autor:
Edward S. Kim, Jeffrey S. Kneisl, Joshua C. Patt, Colin J. Anderson, Nury M. Steuerwald, James T. Symanowski, Xhevahire Begic, Emily A. Baldrige, Deirdre M. Maxwell, David M. Foureau, Carol J. Farhangfar, Jennifer H. Benbow, William A. Ahrens, Myra M. Robinson, Megan H. Jagosky, Michael B. Livingston
Treatment Emergent Adverse Events Attributed to Pembrolizumab, Any Grade.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf832be93579c2f32e46091b3577a41b
https://doi.org/10.1158/1078-0432.22483110.v1
https://doi.org/10.1158/1078-0432.22483110.v1
Autor:
Edward S. Kim, Jeffrey S. Kneisl, Joshua C. Patt, Colin J. Anderson, Nury M. Steuerwald, James T. Symanowski, Xhevahire Begic, Emily A. Baldrige, Deirdre M. Maxwell, David M. Foureau, Carol J. Farhangfar, Jennifer H. Benbow, William A. Ahrens, Myra M. Robinson, Megan H. Jagosky, Michael B. Livingston
All Treatment Emergent Adverse Events Regardless of Causality, Any Grade
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7850331292f3a8df2d0b89871ed91528
https://doi.org/10.1158/1078-0432.22483116.v1
https://doi.org/10.1158/1078-0432.22483116.v1
Autor:
Edward S. Kim, Jeffrey S. Kneisl, Joshua C. Patt, Colin J. Anderson, Nury M. Steuerwald, James T. Symanowski, Xhevahire Begic, Emily A. Baldrige, Deirdre M. Maxwell, David M. Foureau, Carol J. Farhangfar, Jennifer H. Benbow, William A. Ahrens, Myra M. Robinson, Megan H. Jagosky, Michael B. Livingston
Purpose:Doxorubicin is standard therapy for advanced soft-tissue sarcoma (STS) with minimal improvement in efficacy and increased toxicity with addition of other cytotoxic agents. Pembrolizumab monotherapy has demonstrated modest activity and tolerab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20971f5acf9784dd02c761e4e33482dc
https://doi.org/10.1158/1078-0432.c.6531075.v1
https://doi.org/10.1158/1078-0432.c.6531075.v1
Autor:
Edward S. Kim, Jeffrey S. Kneisl, Joshua C. Patt, Colin J. Anderson, Nury M. Steuerwald, James T. Symanowski, Xhevahire Begic, Emily A. Baldrige, Deirdre M. Maxwell, David M. Foureau, Carol J. Farhangfar, Jennifer H. Benbow, William A. Ahrens, Myra M. Robinson, Megan H. Jagosky, Michael B. Livingston
Study inclusion and exclusion criteria.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::daecebe2176fecba4b25c38c536c6195
https://doi.org/10.1158/1078-0432.22483107
https://doi.org/10.1158/1078-0432.22483107
Autor:
Edward S. Kim, Jeffrey S. Kneisl, Joshua C. Patt, Colin J. Anderson, Nury M. Steuerwald, James T. Symanowski, Xhevahire Begic, Emily A. Baldrige, Deirdre M. Maxwell, David M. Foureau, Carol J. Farhangfar, Jennifer H. Benbow, William A. Ahrens, Myra M. Robinson, Megan H. Jagosky, Michael B. Livingston
Treatment Emergent Adverse Events Attributed to Either Doxorubicin, Pembrolizumab, or Both, Any Grade
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::251f8b19db42a7cbd1ed256ffe206398
https://doi.org/10.1158/1078-0432.22483113.v1
https://doi.org/10.1158/1078-0432.22483113.v1
Autor:
Robby Turk, Landon Bulloch, Joshua C. Patt, Colin J. Anderson, Malcolm H. Squires, Jeffrey S. Kneisl
Publikováno v:
Techniques in Orthopaedics. 38:50-52
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8d8fef0b5b93690b27f76d24f7df646c
https://doi.org/10.1097/bto.0000000000000602
https://doi.org/10.1097/bto.0000000000000602
Autor:
Michael B. Livingston, David M. Foureau, Colin J. Anderson, Edward S. Kim, Emily Baldrige, Megan Jagosky, Jennifer H Benbow, Jeffrey S. Kneisl, Xhevahire Begic, Myra M. Robinson, James T. Symanowski, Nury Steuerwald, Joshua C. Patt, Carol J. Farhangfar, Deirdre M. Maxwell, William A. Ahrens
Publikováno v:
Clinical Cancer Research. 27:6424-6431
Purpose: Doxorubicin is standard therapy for advanced soft-tissue sarcoma (STS) with minimal improvement in efficacy and increased toxicity with addition of other cytotoxic agents. Pembrolizumab monotherapy has demonstrated modest activity and tolera
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f77fe4434b207b40c8e6b3ee9b63fd12
https://doi.org/10.1158/1078-0432.ccr-21-2001
https://doi.org/10.1158/1078-0432.ccr-21-2001